PREDNOS Secondary outcome measures

	SC group (N=109)	EC group (N=114)	Estimate (95% CI)	p-value
Relapses				
Number of relapses	394	454		
Number of participants experiencing a relapse	88 (81%)	91 (80%)	HR: 0.87 (0.65-1.17)	0.3
Mean (SD) number of relapses per participant	3.61 (3.25)	3.98 (3.30)	IRR:1.09 (0.86-1.39)	0.5
Number of participants who developed FRNS	55 (50%)	60 (53%)	RR: 1.04 (0.81-1.35)	0.7
Number of participants who developed SDNS	48 (44%)	48 (42%)	RR: 0.96 (0.71-1.29)	0.8
Second line immunosuppressive agents				
Number of participants who received second line immunosuppressants	61 (56%)	62 (54%)	RR: 0.97 (0.77, 1.23)	0.8
Type of immunosuppressant received				
Ciclosporin	6 (6%)	4 (4%)		
Tacrolimus	8 (7%)	18 (16%)		
Levamisole	35 (32%)	34 (30%)		
Cyclophosphamide	31 (28%)	29 (25%)		
Mycophenolate mofetil	13 (12%)	15 (13%)		
Rituximab	5 (5%)	1 (1%)		
Corticosteroid dose	N=90	N=94		
Mean (SD) total prednisolone dose (mg)†	5474.6 (3697.3)	6674.1 (4998.2)	Mean difference=1199.5 (-83.8-2482.8)	0.07

SD=Standard deviation; CI=Confidence Interval; HR=Hazard Ratio; IIR=Incident Rate Ratio; RR=Relative Risk.

A ratio less than 1 favours the EC group. A negative mean difference favours the EC group.

† Total dose of prednisolone received during the study (following completion of study medication).